Düsseldorf, September 2023 – expopharm, Europe’s leading trade fair for the pharmaceutical market, is once again the central meeting place for industry insiders in Düsseldorf this year. In addition to a comprehensive range of pharmaceutical products and services, this year HAPA pharm presented its innovative dosage forms for medicinal cannabis developed with pharmacists, including inhalation
We are excited to announce that HAPA is now a member of the European Medicinal Cannabis Association (EUMCA). The EUMCA is the authoritative voice for the medicinal cannabis industry sector in Europe, and we are proud to now be a part of this important organization. Sita Schubert, the founder and general secretary of the EUMCA,
Dear Investors, we appreciate your continued support and interest in HAPA pharm. We are pleased to share with you the latest developments of our company and our future plans.
Raphael Mechoulam was born in Sofia, Bulgaria, on November 5, 1930. The son of Jewish immigrants from Bulgaria, he grew up in Israel. He studied at the Hebrew University of Jerusalem, where he later began his career as a scientist. After completing his studies in 1952, Mechoulam worked as an officer in the Israeli army
Dortmund, January 2023 – HAPA Pharm GmbH is expanding its management team: from January 2023, industry pioneer Alexander Rieg will support the internationally active company as Chief Operating Officer. Alexander Rieg has been an integral part of the medical cannabis industry in Germany for years. Not only is he the founder of `GECA Pharma GmbH’,
HAPA pharm (“HAPA” or the “Company”) operates production facilities in North Macedonia to grow and process medical cannabis for the sale of pharmaceutical cannabis flos and extracts. On May 1st 2020, the Company has successfully received GMP (Good Manufacturing Practice) approval for both facilities.This milestone demonstrates HAPA’s commitment towards stringent quality assurance on premises and
HAPA pharm is actively responding to the situation of coronavirus (COVID-19) by following the recommendations of local and international authorities. We have proactively implemented measures that give priority to the health and safety of our employees, customers and partners, including restricted business travel and access to our sites, improved safety and hygiene, and the ability
HAPA pharm is an internationally active company focusing on the research, development and marketing of cannabinoid-containing products and drug formulations. The company, which previously operated under the name of HAPA Medical, has established itself as a pharmaceutical producer. With its own cultivation of cannabis plants in Europe, the company stands for the quality of all
Käfer Dachgarten-Restaurant im Deutschen Bundestag Demnächst steht in Deutschland mit dem HAPA medical Vollspektrum Cannabis Extrakt THC2.5 CBD2.5 (Lösung) ein neues Extrakt zur Herstellung eines Rezepturarzneimittels aus medizinischem Cannabis zur Verfügung. Daher laden wir Journalisten der medizinischen Fachpresse herzlich zur Launch-Fachpresseveranstaltung ein: Aus Cannabis wird Medizin – Neues orales Cannabis Extrakt THC2,5:CBD2,5 (Lösung) Montag, 12.
HAPA medical partners with Australian Zelda Therapeutics for the advancement of clinical cannabinoid research While experimental studies have already unveiled many mechanisms of action for a wide array of cannabinoids, there is still a lack of proper clinical trials which hinders the practical therapeutic application of cannabinoid medicine. Our partner Zelda Therapeutics brings together some
This content is currently only available in German.
Lieber Arzt, Lieber Apotheker,
im Passwort-geschützten Bereich unserer Website haben wir zahlreiche wertvolle Artikel für Sie zur Verfügung gestellt. Unter anderem finden Sie Informationen zu folgenden Themen: